Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-10
DOI
10.3389/fimmu.2021.689472
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll)
- (2021) Ishwarya Murali et al. BLOOD
- Revisiting Richter transformation in the era of novel CLL agents
- (2021) Anna Petrackova et al. BLOOD REVIEWS
- BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
- (2021) H. Yesid Estupiñán et al. LEUKEMIA
- Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
- (2021) H. Yesid Estupiñán et al. Frontiers in Cell and Developmental Biology
- FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia
- (2021) Vaclav Seda et al. BLOOD
- Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency
- (2021) Henry Y. Lu et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer
- (2021) Teresa Sadras et al. MOLECULAR CELL
- Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice
- (2021) Lin Wang et al. NATURE GENETICS
- Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
- (2021) Xiaohong Zhao et al. Cell Reports
- BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
- (2020) Sasanka M. Handunnetti et al. BLOOD
- Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma
- (2020) Anne Durandy et al. BLOOD
- Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemia
- (2020) Cristina Jiménez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Severe combined immunodeficiency caused by inositol-trisphosphate 3-kinase B (ITPKB) deficiency
- (2020) Abduarahman Almutairi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification
- (2020) Aziz Bousfiha et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies
- (2020) Steven P. Treon et al. JOURNAL OF CLINICAL ONCOLOGY
- Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
- (2020) André F. Rendeiro et al. Nature Communications
- The Frequency of Ras Mutations in Cancer
- (2020) Ian A. Prior et al. CANCER RESEARCH
- Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study
- (2020) John C. Byrd et al. CLINICAL CANCER RESEARCH
- Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells
- (2020) Martin Wist et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
- (2020) H. Yesid Estupiñán et al. Blood Advances
- Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
- (2020) Andreas Agathangelidis et al. BLOOD
- Multiplexed Functional Assessment of Genetic Variants in CARD11
- (2020) Iana Meitlis et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
- (2020) Jenny Klintman et al. BLOOD
- Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy
- (2020) Anthony R. Mato et al. BLOOD
- Management of Waldenström macroglobulinemia in 2020
- (2020) Jorge J. Castillo et al. Hematology-American Society of Hematology Education Program
- Dominant-negative CARD11 mutations: beyond atopy
- (2019) Vivien Béziat et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Commonality despite exceptional diversity in the baseline human antibody repertoire
- (2019) Bryan Briney et al. NATURE
- Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study
- (2019) Anne Quinquenel et al. BLOOD
- Dissection of Subclonal Evolution by Temporal Mutation Profiling in Chronic Lymphocytic Leukemia Patients Treated With Ibrutinib
- (2019) Ambrus Gángó et al. INTERNATIONAL JOURNAL OF CANCER
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
- (2019) Jan A. Burger et al. LEUKEMIA
- Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
- (2019) Isha Kapoor et al. Cell Death & Disease
- The Rasopathy family: Consequences of germline activation of the RAS/MAPK pathway
- (2018) Mylène Tajan et al. ENDOCRINE REVIEWS
- A multiprotein supercomplex controlling oncogenic signalling in lymphoma
- (2018) James D. Phelan et al. NATURE
- Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
- (2018) Roland Schmitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression
- (2018) Narmeen N. Fathi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Mutations in RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
- (2018) Neus Giménez et al. HAEMATOLOGICA
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- The CBM-opathies—A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex
- (2018) Henry Y. Lu et al. Frontiers in Immunology
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
- (2018) Rashmi Kanagal-Shamanna et al. CANCER
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
- (2018) Matthew S Davids et al. Lancet Haematology
- Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
- (2017) Philip A Thompson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib
- (2017) Christine Wolf et al. INTERNATIONAL JOURNAL OF CANCER
- Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
- (2017) C.I. Edvard Smith SEMINARS IN CANCER BIOLOGY
- The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
- (2017) Dan A. Landau et al. Nature Communications
- Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
- (2017) Xiaohong Zhao et al. Nature Communications
- Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
- (2016) Nakhle S. Saba et al. BLOOD
- Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis
- (2016) G. Pavlasova et al. BLOOD
- Clonal B cells in Waldenström’s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling
- (2016) K V Argyropoulos et al. LEUKEMIA
- Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
- (2016) A Hamasy et al. LEUKEMIA
- Antigen receptor stereotypy in chronic lymphocytic leukemia
- (2016) K Stamatopoulos et al. LEUKEMIA
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- From identification of the BTK kinase to effective management of leukemia
- (2016) C I E Smith ONCOGENE
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
- (2016) Shruti Sharma et al. Oncotarget
- Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
- (2016) Chenglin Wu et al. Oncotarget
- Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
- (2015) T.-M. Liu et al. BLOOD
- Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor
- (2015) Corina E. Antal et al. CELL
- Rac-mediated Stimulation of Phospholipase Cγ2Amplifies B Cell Receptor-induced Calcium Signaling
- (2015) Claudia Walliser et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia
- (2015) S-S Chen et al. LEUKEMIA
- Non-coding recurrent mutations in chronic lymphocytic leukaemia
- (2015) Xose S. Puente et al. NATURE
- Mutations driving CLL and their evolution in progression and relapse
- (2015) Dan A. Landau et al. NATURE
- Integrated molecular analysis of adult T cell leukemia/lymphoma
- (2015) Keisuke Kataoka et al. NATURE GENETICS
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targets for Ibrutinib Beyond B Cell Malignancies
- (2015) A. Berglöf et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
- (2014) D. Wodarz et al. BLOOD
- Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma
- (2014) Kenji Ishitsuka et al. LANCET ONCOLOGY
- The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia
- (2014) Y Cao et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
- (2014) N. L. Komarova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
- (2013) B. Y. Chang et al. BLOOD
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- Agammaglobulinemia: causative mutations and their implications for novel therapies
- (2013) Anna Berglöf et al. Expert Review of Clinical Immunology
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- B cell receptor signaling in chronic lymphocytic leukemia
- (2013) Jan A. Burger et al. TRENDS IN IMMUNOLOGY
- A Hypermorphic Missense Mutation in PLCG2 , Encoding Phospholipase Cγ2, Causes a Dominantly Inherited Autoinflammatory Disease with Immunodeficiency
- (2012) Qing Zhou et al. AMERICAN JOURNAL OF HUMAN GENETICS
- The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia
- (2012) C. Le Roy et al. BLOOD
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
- (2012) M. F. M. de Rooij et al. BLOOD
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Congenital B cell lymphocytosis explained by novel germlineCARD11mutations
- (2012) Andrew L. Snow et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
- (2012) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel N-ethyl-N-nitrosourea-induced mutation in phospholipase Cγ2 causes inflammatory arthritis, metabolic defects, and male infertility in vitro in a murine model
- (2011) Koichiro Abe et al. ARTHRITIS AND RHEUMATISM
- Irreversible Protein Kinase Inhibitors
- (2011) L. Garuti et al. CURRENT MEDICINAL CHEMISTRY
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation and Function of NF-κB Transcription Factors in the Immune System
- (2009) Sivakumar Vallabhapurapu et al. Annual Review of Immunology
- Characterization of Phospholipase Cγ Enzymes with Gain-of-Function Mutations
- (2009) Katy L. Everett et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An Oligomeric Signaling Platform Formed by the Toll-like Receptor Signal Transducers MyD88 and IRAK-4
- (2009) Precious G. Motshwene et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF- B
- (2008) L. Yu et al. BLOOD
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pyogenic Bacterial Infections in Humans with MyD88 Deficiency
- (2008) H. von Bernuth et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now